Clinical Trial Leadership: Prof. Wu is the principal investigator of the GC203 clinical trial evaluating TIL therapy for recurrent ovarian cancer. GC203 is exploring the potential of TIL therapy for gynecologic malignancies, an area with significant unmet medical need.
Prof. Xiaohua Wu leads the GC203 clinical trial investigating TIL therapy for patients with recurrent ovarian cancer. This study represents one of the first clinical applications of TIL therapy in gynecologic malignancies and builds on Prof. Wu's extensive experience in ovarian cancer surgery and clinical research.
Leading the first TIL therapy clinical trial in China specifically targeting gynecologic malignancies. The study evaluates the safety and preliminary efficacy of GC101-based TIL therapy in patients with recurrent ovarian cancer who have progressed after platinum-based chemotherapy.
As Director of Gynecologic Oncology at one of China's leading cancer centers, Prof. Wu oversees the largest gynecologic oncology service in the region, managing a high-volume surgical and clinical practice spanning ovarian, cervical, and endometrial cancers.
Prof. Wu's research focuses on improving outcomes for patients with gynecologic malignancies through innovative surgical techniques and novel therapeutic strategies. His group has been instrumental in establishing clinical pathways for cell therapy in ovarian cancer, a disease where effective treatment options after platinum resistance remain extremely limited.
Learn more about GC203 and other TIL therapy options for gynecologic malignancies.
Contact us →